VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Identifieur interne : 001469 ( Main/Exploration ); précédent : 001468; suivant : 001470VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Auteurs : David S. Siegel [États-Unis] ; Meletios Dimopoulos [Grèce] ; Sundar Jagannath [États-Unis] ; Hartmut Goldschmidt [Allemagne] ; Simon Durrant [Australie] ; Jonathan L. Kaufman [États-Unis] ; Xavier Leleu [France] ; Arnon Nagler [Israël] ; Fritz Offner [Belgique] ; Thorsten Graef [États-Unis] ; Joseph E. Eid [États-Unis] ; Jennifer Houp [États-Unis] ; Christine Gause [États-Unis] ; Scott Vuocolo [États-Unis] ; Kenneth C. Anderson [États-Unis]Source :
- Clinical lymphoma, myeloma & leukemia [ 2152-2669 ] ; 2016.
Descripteurs français
- KwdFr :
- Acides hydroxamiques (administration et posologie), Analyse de survie, Bortézomib (administration et posologie), Femelle, Humains, Myélome multiple (anatomopathologie), Myélome multiple (mortalité), Myélome multiple (traitement médicamenteux), Mâle, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Reprise du traitement, Récidive, Résistance aux médicaments antinéoplasiques, Résultat thérapeutique.
- MESH :
- administration et posologie : Acides hydroxamiques, Bortézomib.
- anatomopathologie : Myélome multiple.
- effets indésirables : Protocoles de polychimiothérapie antinéoplasique.
- mortalité : Myélome multiple.
- traitement médicamenteux : Myélome multiple.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Analyse de survie, Femelle, Humains, Mâle, Reprise du traitement, Récidive, Résistance aux médicaments antinéoplasiques, Résultat thérapeutique.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bortezomib (administration & dosage), Drug Resistance, Neoplasm, Female, Humans, Hydroxamic Acids (administration & dosage), Male, Multiple Myeloma (drug therapy), Multiple Myeloma (mortality), Multiple Myeloma (pathology), Recurrence, Retreatment, Survival Analysis, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Bortezomib, Hydroxamic Acids.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Multiple Myeloma.
- mortality : Multiple Myeloma.
- pathology : Multiple Myeloma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Drug Resistance, Neoplasm, Female, Humans, Male, Recurrence, Retreatment, Survival Analysis, Treatment Outcome.
Abstract
The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents.
DOI: 10.1016/j.clml.2016.02.042
PubMed: 27025160
Affiliations:
- Allemagne, Australie, Belgique, France, Grèce, Israël, États-Unis
- Attique (région), Bade-Wurtemberg, District de Karlsruhe, Géorgie (États-Unis), Hauts-de-France, Massachusetts, New Jersey, Nord-Pas-de-Calais, État de New York
- Athènes, Heidelberg, Lille
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001D35
- to stream PubMed, to step Curation: 001D11
- to stream PubMed, to step Checkpoint: 001D11
- to stream Ncbi, to step Merge: 003339
- to stream Ncbi, to step Curation: 003339
- to stream Ncbi, to step Checkpoint: 003339
- to stream Main, to step Merge: 001464
- to stream Main, to step Curation: 001469
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.</title><author><name sortKey="Siegel, David S" sort="Siegel, David S" uniqKey="Siegel D" first="David S" last="Siegel">David S. Siegel</name><affiliation wicri:level="2"><nlm:affiliation>Myeloma Division, Hackensack University Medical Center, Hackensack, NJ. Electronic address: dsiegel@hackensackumc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Myeloma Division, Hackensack University Medical Center, Hackensack</wicri:cityArea></affiliation></author><author><name sortKey="Dimopoulos, Meletios" sort="Dimopoulos, Meletios" uniqKey="Dimopoulos M" first="Meletios" last="Dimopoulos">Meletios Dimopoulos</name><affiliation wicri:level="3"><nlm:affiliation>Department of Therapeutics, University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Therapeutics, University of Athens, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Jagannath, Sundar" sort="Jagannath, Sundar" uniqKey="Jagannath S" first="Sundar" last="Jagannath">Sundar Jagannath</name><affiliation wicri:level="2"><nlm:affiliation>Mount Sinai Medical Center, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Mount Sinai Medical Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name><affiliation wicri:level="3"><nlm:affiliation>Universitätsklinikum Heidelberg, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätsklinikum Heidelberg, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation wicri:level="1"><nlm:affiliation>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L" last="Kaufman">Jonathan L. Kaufman</name><affiliation wicri:level="2"><nlm:affiliation>Emory University School of Medicine, Atlanta, GA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name><affiliation wicri:level="3"><nlm:affiliation>Service des Maladies du Sang, University of Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service des Maladies du Sang, University of Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer</wicri:regionArea><wicri:noRegion>Tel Hashomer</wicri:noRegion></affiliation></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><affiliation wicri:level="1"><nlm:affiliation>Universitair Ziekenhuis Gent, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Universitair Ziekenhuis Gent, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Eid, Joseph E" sort="Eid, Joseph E" uniqKey="Eid J" first="Joseph E" last="Eid">Joseph E. Eid</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Houp, Jennifer" sort="Houp, Jennifer" uniqKey="Houp J" first="Jennifer" last="Houp">Jennifer Houp</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Gause, Christine" sort="Gause, Christine" uniqKey="Gause C" first="Christine" last="Gause">Christine Gause</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Vuocolo, Scott" sort="Vuocolo, Scott" uniqKey="Vuocolo S" first="Scott" last="Vuocolo">Scott Vuocolo</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C" last="Anderson">Kenneth C. Anderson</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27025160</idno><idno type="pmid">27025160</idno><idno type="doi">10.1016/j.clml.2016.02.042</idno><idno type="wicri:Area/PubMed/Corpus">001D35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D35</idno><idno type="wicri:Area/PubMed/Curation">001D11</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D11</idno><idno type="wicri:Area/PubMed/Checkpoint">001D11</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D11</idno><idno type="wicri:Area/Ncbi/Merge">003339</idno><idno type="wicri:Area/Ncbi/Curation">003339</idno><idno type="wicri:Area/Ncbi/Checkpoint">003339</idno><idno type="wicri:Area/Main/Merge">001464</idno><idno type="wicri:Area/Main/Curation">001469</idno><idno type="wicri:Area/Main/Exploration">001469</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.</title><author><name sortKey="Siegel, David S" sort="Siegel, David S" uniqKey="Siegel D" first="David S" last="Siegel">David S. Siegel</name><affiliation wicri:level="2"><nlm:affiliation>Myeloma Division, Hackensack University Medical Center, Hackensack, NJ. Electronic address: dsiegel@hackensackumc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Myeloma Division, Hackensack University Medical Center, Hackensack</wicri:cityArea></affiliation></author><author><name sortKey="Dimopoulos, Meletios" sort="Dimopoulos, Meletios" uniqKey="Dimopoulos M" first="Meletios" last="Dimopoulos">Meletios Dimopoulos</name><affiliation wicri:level="3"><nlm:affiliation>Department of Therapeutics, University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Therapeutics, University of Athens, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Jagannath, Sundar" sort="Jagannath, Sundar" uniqKey="Jagannath S" first="Sundar" last="Jagannath">Sundar Jagannath</name><affiliation wicri:level="2"><nlm:affiliation>Mount Sinai Medical Center, New York, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Mount Sinai Medical Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name><affiliation wicri:level="3"><nlm:affiliation>Universitätsklinikum Heidelberg, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Universitätsklinikum Heidelberg, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation wicri:level="1"><nlm:affiliation>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L" last="Kaufman">Jonathan L. Kaufman</name><affiliation wicri:level="2"><nlm:affiliation>Emory University School of Medicine, Atlanta, GA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Emory University School of Medicine, Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name><affiliation wicri:level="3"><nlm:affiliation>Service des Maladies du Sang, University of Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service des Maladies du Sang, University of Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hematology Division, Chaim Sheba Medical Center, Tel Hashomer</wicri:regionArea><wicri:noRegion>Tel Hashomer</wicri:noRegion></affiliation></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><affiliation wicri:level="1"><nlm:affiliation>Universitair Ziekenhuis Gent, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Universitair Ziekenhuis Gent, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Eid, Joseph E" sort="Eid, Joseph E" uniqKey="Eid J" first="Joseph E" last="Eid">Joseph E. Eid</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Houp, Jennifer" sort="Houp, Jennifer" uniqKey="Houp J" first="Jennifer" last="Houp">Jennifer Houp</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Gause, Christine" sort="Gause, Christine" uniqKey="Gause C" first="Christine" last="Gause">Christine Gause</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Vuocolo, Scott" sort="Vuocolo, Scott" uniqKey="Vuocolo S" first="Scott" last="Vuocolo">Scott Vuocolo</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Merck & Co., Inc., Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C" last="Anderson">Kenneth C. Anderson</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author></analytic><series><title level="j">Clinical lymphoma, myeloma & leukemia</title><idno type="eISSN">2152-2669</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bortezomib (administration & dosage)</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Hydroxamic Acids (administration & dosage)</term><term>Male</term><term>Multiple Myeloma (drug therapy)</term><term>Multiple Myeloma (mortality)</term><term>Multiple Myeloma (pathology)</term><term>Recurrence</term><term>Retreatment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides hydroxamiques (administration et posologie)</term><term>Analyse de survie</term><term>Bortézomib (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Myélome multiple (anatomopathologie)</term><term>Myélome multiple (mortalité)</term><term>Myélome multiple (traitement médicamenteux)</term><term>Mâle</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Reprise du traitement</term><term>Récidive</term><term>Résistance aux médicaments antinéoplasiques</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bortezomib</term><term>Hydroxamic Acids</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides hydroxamiques</term><term>Bortézomib</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Myélome multiple</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Myélome multiple</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myélome multiple</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Male</term><term>Recurrence</term><term>Retreatment</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Reprise du traitement</term><term>Récidive</term><term>Résistance aux médicaments antinéoplasiques</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>France</li><li>Grèce</li><li>Israël</li><li>États-Unis</li></country><region><li>Attique (région)</li><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li><li>Géorgie (États-Unis)</li><li>Hauts-de-France</li><li>Massachusetts</li><li>New Jersey</li><li>Nord-Pas-de-Calais</li><li>État de New York</li></region><settlement><li>Athènes</li><li>Heidelberg</li><li>Lille</li></settlement></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Siegel, David S" sort="Siegel, David S" uniqKey="Siegel D" first="David S" last="Siegel">David S. Siegel</name></region><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C" last="Anderson">Kenneth C. Anderson</name><name sortKey="Eid, Joseph E" sort="Eid, Joseph E" uniqKey="Eid J" first="Joseph E" last="Eid">Joseph E. Eid</name><name sortKey="Gause, Christine" sort="Gause, Christine" uniqKey="Gause C" first="Christine" last="Gause">Christine Gause</name><name sortKey="Graef, Thorsten" sort="Graef, Thorsten" uniqKey="Graef T" first="Thorsten" last="Graef">Thorsten Graef</name><name sortKey="Houp, Jennifer" sort="Houp, Jennifer" uniqKey="Houp J" first="Jennifer" last="Houp">Jennifer Houp</name><name sortKey="Jagannath, Sundar" sort="Jagannath, Sundar" uniqKey="Jagannath S" first="Sundar" last="Jagannath">Sundar Jagannath</name><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L" last="Kaufman">Jonathan L. Kaufman</name><name sortKey="Vuocolo, Scott" sort="Vuocolo, Scott" uniqKey="Vuocolo S" first="Scott" last="Vuocolo">Scott Vuocolo</name></country><country name="Grèce"><region name="Attique (région)"><name sortKey="Dimopoulos, Meletios" sort="Dimopoulos, Meletios" uniqKey="Dimopoulos M" first="Meletios" last="Dimopoulos">Meletios Dimopoulos</name></region></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name></region></country><country name="Australie"><noRegion><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name></noRegion></country><country name="France"><region name="Hauts-de-France"><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name></region></country><country name="Israël"><noRegion><name sortKey="Nagler, Arnon" sort="Nagler, Arnon" uniqKey="Nagler A" first="Arnon" last="Nagler">Arnon Nagler</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001469 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001469 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27025160
|texte= VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27025160" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |